Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study

Kensei Yamaguchi¹ · Narikazu Boku² · Kei Muro³ · Kazuhiro Yoshida⁴ · Hideo Baba⁵ · Shinji Tanaka⁶ · Ayumi Akamatsu⁶ · Takeshi Sano⁷

Published online: 9 November 2021

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2021

Correction to: Gastric Cancer

<https://doi.org/10.1007/s10120-021-01244-y>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

In the original publication of the article, the affiliation “Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd, Osaka, Japan” should be deleted for the co-author “Hideo Baba”.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s10120-021-01244-y>.

✉ Kensei Yamaguchi
kensei.yamaguchi@jfc.or.jp

¹ Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-Ku, Tokyo 135-8550, Japan

² Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

³ Department of Clinical Oncology, Aichi Cancer Center, Nagoya, Japan

⁴ Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, Japan

⁵ Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

⁶ Pharmacovigilance Division, Ono Pharmaceutical Co., Ltd, Osaka, Japan

⁷ Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan